BioSpace News Archive

Aethlon Medical, Inc. (Nasdaq: AEMD) today announced that it has received clearance from the Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company’s Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2023 financial results on Monday, November 6, 2023 after the financial markets close.

Salix Pharmaceuticals today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021.

MAIA Biotechnology, Inc. today announced that its lead asset THIO showed highly potent anticancer activity in gliomas, an aggressive type of brain tumor that originates from glial cells.

Biotricity, Inc. today announced its patent filing for the company’s Bioheart device.

Apnimed, Inc. announced the publication of the full, clinically-significant results from the MARIPOSA Phase 2b trial in the American Journal of Respiratory and Critical Care Medicine, a premier journal in pulmonary, critical care and sleep medicine.

Carmot Therapeutics, Inc. today announced preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.

AbbVie (NYSE: ABBV) will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17.

Anika Therapeutics, Inc. announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.

Zetagen Therapeutics today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.